Simplifying Global Compliance
FDAnews Drug Daily Bulletin
Panel Overwhelmingly Supports Boehringer COPD Drug Striverdi
Jan. 31, 2013
An FDA advisory panel voted 15–1 with one abstention that Boehringer Ingelheim’s (BI) long-acting inhaler Striverdi Respimat has an acceptable risk-benefit profile as a maintenance treatment for chronic obstructive pulmonary disease (COPD). The Pulmonary-Allergy Drugs Advisory Committee (PADAC) gave two more identical votes Wednesday on the drug’s efficacy profile and safety profile.
Drug Industry Daily
Copyright ©2019. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing